Clinical Trial Update: Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating Akynzeo (netupitant/palonosetron) as an antiemetic in patients with endometrial cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Akynzeo (netupitant/palonosetron)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Endometrial Cancer | Phase 4 | Status: RECRUITING